Solstein Capital LLC Has $49,000 Stock Position in Danaher Co. (NYSE:DHR)

Solstein Capital LLC lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 28.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 175 shares of the conglomerate’s stock after selling 69 shares during the period. Solstein Capital LLC’s holdings in Danaher were worth $49,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of DHR. Vanguard Group Inc. raised its stake in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Swedbank AB bought a new position in shares of Danaher during the first quarter valued at $676,545,000. TD Asset Management Inc raised its stake in shares of Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after acquiring an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Danaher Trading Up 0.9 %

Shares of DHR stock opened at $247.76 on Monday. Danaher Co. has a 52-week low of $190.95 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a 50-day simple moving average of $266.95 and a two-hundred day simple moving average of $260.66. The company has a market capitalization of $178.95 billion, a price-to-earnings ratio of 47.28, a PEG ratio of 4.51 and a beta of 0.85.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 earnings per share. Research analysts anticipate that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on DHR shares. Barclays dropped their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Wells Fargo & Company started coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. The Goldman Sachs Group boosted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.